https://ntp.niehs.nih.gov/go/12447

Target Organs and Levels of Evidence for TR-374

Toxicology and Carcinogenesis Studies of Glycidol (CASRN 556-52-5) In F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Glycidol
556-52-5		 06/27/1989 Gavage
R: 0,38,75, M: 0,25,50 MG/KG/50 PER GROUP		 Papanicolaou Research Institute

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 3/50 34/50 39/50
  • Mammary Gland: FIBROADENOMA 3/50 8/50 7/50
  • Brain: GLIOMA 0/50 5/50 6/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
  • Large Intestines: ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
  • Skin: SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
  • Zymbal Gland: CARCINOMA 1/50 3/50 6/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 3/50 13/50 15/50; DYSPLASIA, EPITHELIAL 0/50 10/50 8/50
  • SPLEEN: FIBROSIS 13/50 34/50 28/50
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Mammary Gland: FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
  • Brain: GLIOMA 0/50 4/50 4/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
  • Clitoral Gland: ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
  • Hematopoietic System: LEUKEMIA 13/50 14/50 20/50
May Have Been Related
  • Glandular Stomach: FIBROSARCOMA 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 1/50 16/50 13/50; DYSPLASIA, EPITHELIAL 0/50 12/50 10/50
  • SPLEEN: FIBROSIS 3/50 14/49 20/50
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
  • Liver: ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
May Have Been Related
  • Urinary Bladder: CARCINOMA 0/50 1/50 1/50
  • Epididymis: SARCOMA 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 3/50 8/50 7/50
  • PREPUTIAL GLAND: CYST 1/50 0/50 7/50
  • KIDNEY: CYST 4/50 11/50 9/50
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
  • Mammary Gland: ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
  • Uterus/Cervix: CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
  • Subcutaneous Tissue: SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 5/50 3/50 11/50